糖尿病人數在世界各地快速成長，研究顯示降低血糖值，可延緩糖尿病的發生及預防糖尿病併發症。西醫在臨床上治療糖尿病的口服降血糖藥（OHA）分為五大類，其中α葡萄糖苷酶抑制劑由於能延緩碳水化合物的消化和吸收，因此能有效降低餐後血糖值。本研究以此機制為基礎，利用固定化接受器動態擷取技術（After Flowing Through Immobilized Receptor, AFTIR）來篩選中草藥中與α葡萄糖苷酶結合的有效成分。
本研究利用綠茶葉及其他中草藥萃取物已成功驗證α-glucosidase-CM5晶片為一高效率、高靈敏度及穩定性佳的藥物篩選平台。另一方面，研究結果顯示紅豆杉阻斷EGCG和α-glucosidase結合的能力雖不明顯（EGCG 阻斷比為35.9%），但其抑制酵素活性的能力顯著（抑制酵素活性百分比為73%），由此顯示出紅豆衫微量的有效成分可能具有極佳的抑制酵素活性能力，因此可視為極具開發潛力的先導藥物；其有效成分的確認及化學結構的解析將是本實驗未來進行的工作。
The number of diabetes patients is growing fast all over the world. Previous reports showed that lowering blood glucose levels may delay the occurrence of diabetes. Western medicines in clinical treatment of diabetes use oral hypoglycemic agents include α-glucosidase inhibitors which can effectively reduce postprandial blood glucose levels. In this study, AFTIR technology via the immobilization of α-glucosidase on chip was used to find several effective herbal extracts and has been verified as an effective method via finding the epicatechin gallate from green tea. Furthermore, the results show that Taxus blocks epigallocatechin gallate and α-glucosidase with blocking ratio of 35.9% and the activity of inhibiting α-glucosidase is significant. With the observations above, Taxus can therefore be a potential agent used for curing the diabetes patients in the future.
